	US 12,102,647 B2
	Citrine pleurotus polysaccharide and applications thereof
Qi Wang, Changchun (CN); Ling Su, Changchun (CN); and Jintao Yang, Changchun (CN)
Assigned to Qi Wang, Changchun (CN)
Filed by Qi Wang, Changchun (CN)
Filed on Dec. 29, 2021, as Appl. No. 17/564,777.
Claims priority of application No. 202111153946.8 (CN), filed on Sep. 29, 2021.
Prior Publication US 2023/0099458 A1, Mar. 30, 2023
Int. Cl. A61K 31/7004 (2006.01); A61K 31/715 (2006.01); A61P 21/00 (2006.01)

CPC A61K 31/7004 (2013.01) [A61K 31/715 (2013.01); A61P 21/00 (2018.01)]

2 Claims

1. A medicine for treating sarcopenia in a subject comprising a mixture of polysaccharide compounds from citrine pleurotus (Pleurotus citrinopileatus); xylose accounts for more than 50% in molar percentage of the citrine pleurotus polysaccharides, glucose accounts for more than 15% in molar percentage of the citrine pleurotus polysaccharides, galactose accounts for more than 4% in molar percentage of the citrine pleurotus polysaccharides, glucuronic acid accounts for more than 1% in molar percentage of the citrine pleurotus polysaccharides, each of the fucose, fructose and arabinose accounts for less than 3% in molar percentage of the citrine pleurotus polysaccharides along with medically acceptable excipients.